STOCK TITAN
  1. Home
  2. Sec-filings
  3. KYMR
  4. [4] – Albers Jeffrey W. (CIK 0001638474)

[4] – Albers Jeffrey W. (CIK 0001638474)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock KYMR logo
Kymera Therapeutics, Inc.

NASDAQ:KYMR

KYMR Rankings

#1510 Ranked by Market Cap
N/A Ranked by Dividends

KYMR Latest News

Sep 17, 2025
Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses
Sep 3, 2025
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
Aug 27, 2025
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Aug 11, 2025
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
Aug 4, 2025
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025

KYMR Latest SEC Filings

Sep 16, 2025
[Form 4] Kymera Therapeutics, Inc. Insider Trading Activity
Sep 16, 2025
[144] Kymera Therapeutics, Inc. SEC Filing
Sep 17, 2025
[144] Kymera Therapeutics, Inc. SEC Filing
Sep 17, 2025
[144] Kymera Therapeutics, Inc. SEC Filing
Sep 17, 2025
[144] Kymera Therapeutics, Inc. SEC Filing

KYMR Stock Data

4.09B
69.20M
2.53%
109.99%
11.42%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WATERTOWN